Paper39199337
Novel Therapeutic Horizons: SNCA Targeting in Parkinson's Disease.
Caramiello AM and 1 other. Biomolecules, 2024. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Novel Therapeutic Horizons: SNCA Targeting in Parkinson's Disease. Papers, record 39199337. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39199337
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| alpha-Synuclein | Major topic |
| Parkinson Disease | Major topic |
| Humans | |
| Animals | |
| Oligonucleotides, Antisense | |
| RNA, Small Interfering | |
| Dopaminergic Neurons |
Source PubMed
References81
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12489851 | Antisense oligonucleotides: basic concepts and mechanisms. | Mol Cancer Ther | 2002 | https://conductscience.org/library/papers/12489851 | PubMed |
| 2 | 27735097 | Copper-Aβ Peptides and Oxidation of Catecholic Substrates: Reactivity and Endogenous Peptide Damage. | Chemistry | 2016 | https://conductscience.org/library/papers/27735097 | PubMed |
| 3 | 28375731 | CRISPR-Cas9 Structures and Mechanisms. | Annu Rev Biophys | 2017 | https://conductscience.org/library/papers/28375731 | PubMed |
| 4 | 25495987 | miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. | Future Med Chem | 2014 | https://conductscience.org/library/papers/25495987 | PubMed |
| 5 | 30906671 | Translational inhibition of α-synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice. | Am J Neurodegener Dis | 2019 | https://conductscience.org/library/papers/30906671 | PubMed |
| 6 | 21221670 | The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. | J Neural Transm (Vienna) | 2011 | https://conductscience.org/library/papers/21221670 | PubMed |
| 7 | 29192260 | Antisense oligonucleotides: the next frontier for treatment of neurological disorders. | Nat Rev Neurol | 2018 | https://conductscience.org/library/papers/29192260 | PubMed |
| 8 | 29669594 | miRNAs regulate immune response and signaling during hepatitis C virus infection. | Eur J Med Res | 2018 | https://conductscience.org/library/papers/29669594 | PubMed |
| 9 | 32954426 | The mechanistic role of alpha-synuclein in the nucleus: impaired nuclear function caused by familial Parkinson's disease SNCA mutations. | Hum Mol Genet | 2020 | https://conductscience.org/library/papers/32954426 | PubMed |
| 10 | 30658149 | Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration. | Neurobiol Dis | 2019 | https://conductscience.org/library/papers/30658149 | PubMed |
| 11 | 31518552 | Advances and challenges in studying noncoding RNA regulation of drug metabolism and development of RNA therapeutics. | Biochem Pharmacol | 2019 | https://conductscience.org/library/papers/31518552 | PubMed |
| 12 | 29243000 | RNA interference-based therapy and its delivery systems. | Cancer Metastasis Rev | 2018 | https://conductscience.org/library/papers/29243000 | PubMed |
| 13 | 27248657 | Constitutive translation of human α-synuclein is mediated by the 5'-untranslated region. | Open Biol | 2016 | https://conductscience.org/library/papers/27248657 | PubMed |
| 14 | 23686823 | Antisense oligonucleotides: treating neurodegeneration at the level of RNA. | Neurotherapeutics | 2013 | https://conductscience.org/library/papers/23686823 | PubMed |
| 15 | 38181056 | Decreasing the intrinsically disordered protein α-synuclein levels by targeting its structured mRNA with a ribonuclease-targeting chimera. | Proc Natl Acad Sci U S A | 2024 | https://conductscience.org/library/papers/38181056 | PubMed |
| 16 | 17603039 | Cell systems and the toxic mechanism(s) of alpha-synuclein. | Exp Neurol | 2008 | https://conductscience.org/library/papers/17603039 | PubMed |
| 17 | 27397479 | Pharmacomodulation of microRNA Expression in Neurocognitive Diseases: Obstacles and Future Opportunities. | Curr Neuropharmacol | 2017 | https://conductscience.org/library/papers/27397479 | PubMed |
| 18 | 27097021 | Inforna 2.0: A Platform for the Sequence-Based Design of Small Molecules Targeting Structured RNAs. | ACS Chem Biol | 2016 | https://conductscience.org/library/papers/27097021 | PubMed |
| 19 | 31866823 | Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. | Front Mol Neurosci | 2019 | https://conductscience.org/library/papers/31866823 | PubMed |
| 20 | 20551914 | In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. | Mol Ther | 2010 | https://conductscience.org/library/papers/20551914 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42378631 | Colorectal Cancer Liver Metastasis-Associated Ferroptosis-Related Genes Modulate Lipid Peroxidation in Colorectal Cancer Cells. | Mol Carcinog | 2026 | https://conductscience.org/library/papers/42378631 | PubMed |
| 42064924 | LIFETIME JEM-DERIVED OCCUPATIONAL EXPOSURE BURDEN AND ODDS OF PARKINSON'S DISEASE AND PARKINSONISM IN A MATCHED CASE-CONTROL STUDY. | medRxiv | 2026 | https://conductscience.org/library/papers/42064924 | PubMed |
| 41929945 | Identification of potential short-chain fatty acid biomarkers in Alzheimer's disease through bioinformatics analysis. | J Alzheimers Dis Rep | 2026 | https://conductscience.org/library/papers/41929945 | PubMed |
| 41596551 | Identification of KHS-101 as a Transcription Factor EB Activator to Promote α-Synuclein Degradation. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41596551 | PubMed |
| 41540050 | Early retinal synaptic dysfunction and proteomic remodeling precede neurodegeneration in a Parkinson's disease model. | NPJ Parkinsons Dis | 2026 | https://conductscience.org/library/papers/41540050 | PubMed |
| 41484831 | Antisense Oligonucleotide Therapeutics Targeting Age-Related Diseases. | BioDrugs | 2026 | https://conductscience.org/library/papers/41484831 | PubMed |
| 41278771 | Targeted α-Synuclein mRNA Degradation by PMO-Based RNA-Degrading Chimeras. | bioRxiv | 2025 | https://conductscience.org/library/papers/41278771 | PubMed |
| 41127543 | Application of biomimetic approaches in the treatment of neurological disorders. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/41127543 | PubMed |
| 41082301 | Progress in Disease-Modifying Therapies for Parkinson's Disease. | Aging Dis | 2025 | https://conductscience.org/library/papers/41082301 | PubMed |
| 41023705 | In vivo validation of novel non-invasive PHP.eB AAVs as a potential therapeutic approach for alpha-synucleinopathies. | Acta Neuropathol Commun | 2025 | https://conductscience.org/library/papers/41023705 | PubMed |
| 40815569 | Alpha-synuclein abundance and localization are regulated by the RNA-binding protein PUMILIO1. | Cell Rep | 2025 | https://conductscience.org/library/papers/40815569 | PubMed |
| 40613913 | A review on current theories and potential therapies for prion diseases. | Mol Biol Rep | 2025 | https://conductscience.org/library/papers/40613913 | PubMed |
| 40589152 | Gaps in the Parkinson's disease therapeutic clinical pipeline: A focus on approaches targeting disease pathobiology. | J Parkinsons Dis | 2026 | https://conductscience.org/library/papers/40589152 | PubMed |
| 39997657 | Therapeutic Role of Heterocyclic Compounds in Neurodegenerative Diseases: Insights from Alzheimer's and Parkinson's Diseases. | Neurol Int | 2025 | https://conductscience.org/library/papers/39997657 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SNCA | 6622 | PubTator's text mining | https://conductscience.org/library/genes/6622 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39199337
GET https://conductscience.org/api/papers/v1/39199337/references?page=2